Published in Clin Chim Acta on December 07, 2007
Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Br J Clin Pharmacol (2010) 0.79
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
Intrarenal resistive index after renal transplantation. N Engl J Med (2013) 4.19
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36
The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis (2009) 2.34
Late referral of patients with chronic kidney disease: no time to waste. Mayo Clin Proc (2006) 2.04
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther (2005) 1.95
Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl (2009) 1.83
Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant (2004) 1.75
Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol (2009) 1.69
p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol (2010) 1.66
Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant (2008) 1.63
Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol (2004) 1.54
Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant (2004) 1.54
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation (2002) 1.50
Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proc Natl Acad Sci U S A (2009) 1.47
A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med (2013) 1.47
Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation (2010) 1.45
Expanding the donor pool to increase renal transplantation. Nephrol Dial Transplant (2004) 1.43
Impact of vascular calcification on corrected QT interval at the time of renal transplantation. Am J Nephrol (2011) 1.42
Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant (2004) 1.38
Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii. Appl Environ Microbiol (2006) 1.36
p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol (2009) 1.36
Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides, and xylooligosaccharides. Crit Rev Food Sci Nutr (2011) 1.36
Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem (2005) 1.35
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation (2006) 1.33
Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection? Transfusion (2007) 1.31
Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol (2010) 1.31
Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant (2007) 1.31
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant (2009) 1.26
Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol (2009) 1.24
Functional analysis of colonic bacterial metabolism: relevant to health? Am J Physiol Gastrointest Liver Physiol (2011) 1.21
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol (2010) 1.21
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation (2005) 1.21
Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis (2009) 1.18
Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int (2003) 1.17
Interference of globin genes with biomarker discovery for allograft rejection in peripheral blood samples. Physiol Genomics (2007) 1.16
Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation (2013) 1.16
Relevance of protein fermentation to gut health. Mol Nutr Food Res (2011) 1.15
Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med (2003) 1.14
Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol (2006) 1.12
Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther (2004) 1.12
A review of albumin binding in CKD. Am J Kidney Dis (2008) 1.11
Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol (2013) 1.10
Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A (2009) 1.10
Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant (2005) 1.09
An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation (2010) 1.08
The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics (2011) 1.08
Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol (2008) 1.07
Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet (2004) 1.06
Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis (2004) 1.06
Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int (2003) 1.06
Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther (2008) 1.05
Predicting renal graft failure using multivariate longitudinal profiles. Biostatistics (2007) 1.05
Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol (2012) 1.05
First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging (2006) 1.03
Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation (2010) 1.02
New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit (2009) 1.01
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) (2010) 1.00
The value of tuberculin skin testing in haemodialysis patients. Nephrol Dial Transplant (2004) 0.99
Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif Organs (2006) 0.99
FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant (2011) 0.99
Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int (2008) 0.98
Calcium metabolism in the early posttransplantation period. Clin J Am Soc Nephrol (2009) 0.97
Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant (2005) 0.97
Uric acid levels have no significant effect on renal function in adult renal transplant recipients: evidence from the symphony study. Clin J Am Soc Nephrol (2009) 0.97
A two-part joint model for the analysis of survival and longitudinal binary data with excess zeros. Biometrics (2007) 0.97
Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflamm Bowel Dis (2011) 0.96
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation (2004) 0.95
Acute rejection in non-compliant renal allograft recipients: a distinct morphology. Clin Transplant (2007) 0.95
Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol Dial Transplant (2011) 0.95
Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation (2007) 0.95
Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics (2008) 0.95
Consumption of breads containing in situ-produced arabinoxylan oligosaccharides alters gastrointestinal effects in healthy volunteers. J Nutr (2012) 0.95
Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis (2005) 0.94
In vitro kinetics of prebiotic inulin-type fructan fermentation by butyrate-producing colon bacteria: implementation of online gas chromatography for quantitative analysis of carbon dioxide and hydrogen gas production. Appl Environ Microbiol (2009) 0.94